Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Siltuximab for CRS and ICANS in CAR T-Cell Therapy
NCT04975555Phase 2Completed
- Sponsor
- University of Alabama at Birmingham
- Start
- Nov 2021
- Primary completion
- Jan 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of siltuximab in cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), sponsored by University of Alabama at Birmingham. Primary endpoint: Participants With a Complete Response for Cytokine Release Syndrome (CRS) at 14 days. Started Nov 2021; status: completed.
02
Drugs
siltuximab
03
Conditions
cytokine release syndrome (CRS)immune effector cell-associated neurotoxicity syndrome (ICANS)
Beyond the preview
Go deeper on NCT04975555.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04975555.